Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Kato, Eri; G. Silverman, Michael; Mosenzon, Ofri; A. Zelniker, Thomas; Cahn, Avivit; H.M. Furtado, Remo; Kuder, Julia; A. Murphy, Sabina; L. Bhatt, Deepak; A. Leiter, Lawrence; K. McGuire, Darren; Wilding, John; P. Bonaca, Marc; T. Ruff, Christian; S. Desai, Akshay; Goto, Shinya; A. Johansson, Peter; Gause‐Nilsson, Ingrid; Johanson, Per; Maria Langkilde, Anna; Raz, Itamar; S. Sabatine, Marc; D. Wiviott, Stephen

doi:10.1161/circulationaha.119.040130

Public

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Published in Circulation • Mar 18, 2019

Authors:

Eri Kato

Michael G. Silverman

Ofri Mosenzon

Abstract

BACKGROUND: In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure (HHF) in a broad population of...

Subject

Dapagliflozin

Medicine

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!